Novartis AG 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NYSE

4 Feb 2026

NVS

Novartis AG

20-F: Novartis Reports Strong 2025 Growth, Strategic Acquisitions

Novartis AG delivered robust financial performance in 2025, driven by strong sales of key innovative medicines and strategic acquisitions, despite facing generic competition for several established products.

NYSE

31 Jan 2025

NVS

Novartis AG

20-F: Novartis AG Files 20-F Report, Details Financial Performance and Strategic Initiatives

Novartis AG released its 20-F filing, outlining its financial results for the year ended December 31, 2024, and providing insights into its strategic direction and operational activities.

NYSE

31 Jan 2024

NVS

Novartis AG

20-F: Novartis AG Details Articles of Incorporation and Corporate Governance in Latest Filing

Novartis AG's recent filing details amendments to its Articles of Incorporation and provides insights into its corporate governance structure.